• Berubicin is CNS Pharmaceuticals’ lead product candidate for treatment of Glioblastoma Multiforme, and has the potential to be the first anthracycline to cross the blood-brain barrier based on limited results from a Phase 1 trial
• The market for GBM treatment is estimated to reach $3.3 billion in 2024, growing at a CAGR of 17.4%
• CNS, in collaboration with sublicensee partner WPD Pharmaceuticals, is currently planning three Berubicin clinical trials, all to start within the year – two Phase II adult trials and a pediatric Phase I trial

Glioblastoma Multiforme (“GBM”) is one of the most aggressive forms of brain cancer in the adult population and is currently considered incurable, with a significant recurrence rate in most patients. Even with gross total resection of the GBM tumor, there is always a microscopic amount of disease that gets left behind. A gross total resection of GBM is defined as removing at least 98% or more of the tumor that has been contrast-enhanced and visible on an MRI.

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, hopes to address this issue and improve the lives of GBM patients while also lowering recurrence risks with its lead drug candidate, Berubicin.

Developed by Dr. Waldemar Priebe, Ph.D., the Chairman of the Scientific Advisory Board for CNS Pharmaceuticals, and a Professor of Medicinal Chemistry at the University of Texas MD Anderson Cancer Center, Berubicin appears (based on limited Phase 1 trial results) to be the first anthracycline to cross the blood-brain barrier (“BBB”) in adults, reaching the tumor’s cancerous cells. Anthracyclines are among some of the most effective drugs ever created for cancer treatment. They have various uses within cancer treatments, including breast, stomach, uterine, ovarian, bladder, lung, and hematological malignancies. To date, there has not been any evidence that anthracyclines can cross the BBB.

In December 2020, the U.S. Food and Drug Administration (“FDA”) cleared CNS Pharmaceuticals’ investigational new drug (“IND”) application. This approval enables the company to begin a human trial and ship Berubicin across state lines to clinical investigators.

CNS Pharmaceuticals is optimistic about the three upcoming clinical trials that are scheduled for Berubicin, and is enthusiastic about the first pediatric study that will begin later this year in Poland under the oversight of sublicensee partner WPD Pharmaceuticals. WPD will also be running a concurrent adult Phase II trial in Poland, while CNS Pharmaceuticals will organize a separate randomized, controlled Phase II adult trial beginning in the United States but slated to expand into western Europe.

Commenting on the plans for the Berubicin development program during a podcast interview with Sid Vaidaya and Eric Gershey, CNS Pharmaceuticals CEO John Climaco said, “This is the biggest news we’ve announced since our IPO back in November 2019. Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials” (https://ibn.fm/4azlQ).

The market for GBM treatment has grown exponentially over the last few years, being expected to reach $3.3 billion by 2024, from $659 million in 2014 (https://ibn.fm/XOkXw). There are multiple companies making progress in this market as a result of increased focus and investment into research and development of GBM therapeutics. With Berubicin’s apparent ability to breach the BBB and the planned Phase I and Phase II trials, CNS Pharmaceuticals is uniquely positioned to capitalize on this market growth and secure a leading role in the sector.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Ideanomics’ Mobility and Capital divisions provide shareholders with access to disruptive and high-growth opportunities
• The company’s primary shareholders include two billionaire families – former chairman Dr. Bruno Wu and Vice Chairman Mr. Shane McMahon
• The company has raised approximately $400 million in six months to fund new investments and acquisitions in revenue-based growth focused on EV and fintech companies
• Ideanomics Mobility consists of five companies and generates revenue from the entire EV ecosystem from vehicle and battery sales to financing, leasing and insurance, all the way through charging and energy services
• The EV market is expected to grow exponentially, driven by growing public acceptance and the current U.S. administration’s support as it works toward a 100% clean-energy economy
• Ideanomics Capital is focused on financial technologies and their disruptive potential across financial services, ranging from markets and digital assets to real estate

Ideanomics (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities. The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (“WAVE”) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses. Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia. Ideanomics Mobility Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028. This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy. The Ideanomics Mobility unit consists of five companies:

• Mobile Energy Global (“MEG”) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (“S2F2C”) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
• Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
• Wireless Advanced Vehicle Electrification (“WAVE”) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
• Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
• Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
• Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (“S2F2C”) business model, which features three operating areas:

1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies. Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv). The Ideanomics Capital unit consists of five companies:

• Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
• The Delaware Board of Trade (“DBOT”) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
• Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
• Technology Metals Market (“TM2”) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
• Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel. Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc. Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank. Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh. Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• LD Micro reconstitutes index to reveal 35.73% increase over 2020, 423 new listings for total of 1,189 companies
• Index includes US and Canadian companies with market cap between $50-300 million, average daily traded value of $50,000 in previous quarter
• LD Micro is subsidiary of SRAX, provider of Sequire SaaS investor analytics platform

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its Sequire SaaS platform, recently announced that its LD Micro subsidiary reconstituted its North American microcap index to reveal a 35.72% increase of 423 new listings for a total of 1,189 companies (https://ibn.fm/a7p3d).

LD screens companies based on selection criteria that include market cap, trading value, listing, and filing information. To qualify for inclusion on its list, companies must be listed in the United States or Canada, have a market cap between $50 million and $300 million, an average daily traded value of $50,000 in the last quarter, and a 10Q or 10K filed in the preceding calendar year (https://ibn.fm/4fQXR).

“I cannot believe what I’ve seen in the past year,” said Chris Lahiji, President of LD Micro (https://ibn.fm/jOYwN). “The LD Micro Index has more than tripled from its March 2020 lows. The tiniest public companies were also some of the biggest winners last year, and already year-to-date. As each day goes by, the Index becomes more and more consequential to the next generation of great companies.”

Lahiji founded LD Micro as an independent resource to the microcap world in 2006, growing it quickly to become the premier event platform in the space. Following the identification of potential synergies with Sequire – SRAX’s SaaS platform that unlocks investor intelligence for private companies – LD micro was acquired by SRAX in September of 2020.

“LD Micro is, without a doubt, one of the most well-known and respected brands in micro-cap,” said SRAX CEO and founder Christopher Miglino. “Chris Lahiji and his team have done an incredible job of creating a loyal community of investors and issuers.”

Sequire empowers public companies with critical insights into the activities of both retail and institutional investors, helping them create and activate successful campaigns aimed at increasing investor engagement. Since 2019, the SaaS platform has grown to over 3 million active users that include investors and traders from over 90 public companies (https://ibn.fm/L8hSO).

In addition to Sequire, SRAX focuses on building the largest and most reliable opted-in data sets that span a broad range of industry verticals. As the power of data continues to increase across the digital landscape, the Company continues to focus on its mission to provide brands and companies across the CPG, luxury, lifestyle and financial spaces with high-quality data that provides key, actionable insights integral to strategic marketing campaigns.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Share purchase agreement will result in Pac Roots acquiring all issued, outstanding shares of Grasstown
• “The Grasstown culture complements PacRoots’ foundation of variety and quality built on the West Coast,” says PACR CEO
• Pac Roots intends to continue — and strengthen — the strong reputation built by the Grasstown brand

Cannabis and motorcycles make an intriguing combination — a combo that Lords of Grasstown Holdings Ltd. has created a whole business around. And now Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) is getting in on the action. The Company recently announced the execution of a share purchase agreement with the shareholders of Lords of Grasstown that will result in Pac Roots acquiring all the issued and outstanding shares of Grasstown (https://ibn.fm/PiCMh). “PacRoots is thrilled to partner with such an incredible brand and story driven by artists with a passionate vision that resonates throughout a massive community,” said PacRoots’ president and CEO Patrick Elliott. “The creators, designers and marketers behind Lords of Grasstown have a truly unique and talented offering that will be invaluable to the PacRoots organization. The Grasstown culture complements PacRoots’ foundation of variety and quality built on the West Coast. This platform brings a tremendous following that embraces these attributes, which are well positioned to excel in BC and California’s West coast marketplaces.” Founded in 2011 and incorporated in 2013, Lords of Gastown is a lifestyle motorcycle brand that first started in the Pacific Northwest. The company filled a gap in the Harley-Davidson street wear and apparel offerings space and quickly landed on Brian Barnes of Barnes Harley-Davidson Canada. Today the company has built partnerships and collaboration with some of America’s oldest and strongest motorcycle brands and has established more than 80 wholesale accounts across North America as well as in Switzerland, Mexico, Australia, Indonesia and Japan. The company’s cannabis connection comes through founder and director Tyler Hazelwood, who has struggled with Crohn’s disease for more than two decades. “Without cannabis I would not be able to be a dedicated single father to my daughter, nor would I have been able to build these brands or ride my motorcycle across North America,” said Hazelwood. “Cannabis is without a doubt my biggest tool in managing Crohn’s symptoms. I feel a sense of obligation to share my experiences and passion in hopes I can help others with IBD.” Following the success of Lords of Gastown Motorcycle Lifestyle brand, the company launched its Lords of Grasstown Cannabis Culture brand in 2013. The brand offers simple, clean, yet edgy street wear apparel and products, including a CBD soap line. In 2015, Grasstown partnered with BC Cannabis Genetics Guru JB to add some of Canada’s highest testing medical cannabis strains to the line. Through the share purchase agreement, Pac Roots intends to continue — and strengthen — the strong reputation built by the Grasstown brand. Pac Roots began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, the Company is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top-quality products. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Industry leaders remain hopeful that 2021 will be positive year for uranium market
• Demand outstrips supply as global push for carbon-free energy source gains momentum amid muted supply
• As the leading U.S. uranium producer, Energy Fuels is ready to leverage growing market opportunity, remain at forefront of U.S. nuclear energy space

After years of stagnation, industry leaders are confident that the uranium market is going through a revival, heading for potentially rapid growth in the coming years. As a leading U.S. uranium producer, Energy Fuels (NYSE American: UUUU) (TSX: EFR) appears poised to seize on the growing calls for nuclear energy to be deployed to help address climate change and reduce air pollution.

Uranium prices have been depressed for several years, as demand dropped after the 2011 Fukushima disaster in Japan. However, supply shortages and the global quest for alternative, low-carbon power sources have renewed interest in this market.

A recent article published by “Investing News” cites industry leaders feeling optimistic about the direction of the market in 2021 on the back of the strong fundamentals that can drive robust growth. Increasingly recognized as an essential part of the clean energy mix, nuclear energy could significantly increase its share of global electricity production from the current 10%. Nuclear provides 20% of U.S. electricity, and 55% of the carbon-free electricity produced in the country.

The uranium price has increased by more than 20% over the past year to around $30 as longer-term fundamentals are expected to remain strong for the sector (https://ibn.fm/MTv5D). Based on cost-curve support calculations, the long-term sustainable uranium spot price is most likely in the $40–$50 per pound range with a potential multiyear spike to $80/lb, according to a recent industry research (https://ibn.fm/ag0AA).

The article features Energy Fuels vice president of marketing and corporate development Curtis Moore, who points out that years of stagnation have potentially led to uranium’s moment as demand continues to exceed supply. Inventory reduction, deposit depletion and continued high grading indicate the potential for strong price performance in the coming years.

Moore also notes that prices are still below the level needed to accelerate production. Despite activity increasing in 2020, there are still inventories available in the market, he notes, but they are being depleted and at some point will need to be replaced. This could happen at a price that incentivizes mine production, and this price is much higher than what we see reported today, he said.

“We think there are definitely better uranium markets ahead,” said Moore. “The realizable sales price for uranium is below most miners’ cost of production, which is unsustainable. In many ways, history is repeating, and we might be in the beginning of the next run in uranium prices. We don’t know when the market will recover, but it will.”

As a leading uranium producer, Energy Fuels appears well positioned to seize the market opportunity as the industry heads for a potential price surge.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Online sales of new TAAT tobacco-free, nicotine-free option totals CDN$100,000 sales in only five days
• TryTAAT site launched on Feb. 17 with cartons of TAAT Original, Smooth and Menthol available for purchase
• “February has been a very productive month for us here at TAAT,” says CEO, citing list of achievements

Within the first five days of the launch of its e-commerce portal, TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) reported that its flagship product — TAAT(TM), a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol —had totaled more than CDN$100,000 in sales, with $48,000 of that coming in the first 48 hours (https://ibn.fm/cyc6O). Those numbers confirm what the TAAT team has known since the launch of the product only two months ago: legal-age smokers are eagerly looking for a nicotine- and tobacco-free smoking experience (https://ibn.fm/0mrwU). A life sciences company committed to providing that kind of smoking experience to adult smokers, TAAT lunched its e-commerce portal last Wednesday at 9 a.m. ET (https://ibn.fm/snLKs). Designed to allow smokers aged 21 years and older to purchase TAAT’s flagship product, the TryTAAT site has delivered beyond what TAAT management expected. “To sell more than CDN$100,000 worth of a relatively new product in such a short period is absolutely exceptional,” said TAAT CEO Setti Coscarella. “Countless smokers aged 21-plus in the United States have been eagerly awaiting the launch of our online store on Wednesday, which I believe has contributed significantly to our product sales this past week.” The site launched on Wednesday, with cartons of TAAT Original, Smooth and Menthol available for purchase by adult-age smokers and shipment to addresses in eligible jurisdictions. Shortly after the initial launch, a Taste Explorer Bundle was added to the site, consisting of one 20-stick pack of each of the three TAAT varities. In addition, the company’s TryTAATpromotion remains active, in which adult smokers in eligible states can request a complimentary sample pack of the TAAT variety of their choice. TAAT is pioneering a new concept with TAAT, its tobacco-free and nicotine-free smoking alternative. TAAT’s base material is Beyond Tobacco, a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. TAAT products were first unveiled in various retail locations throughout Ohio, where an estimated 60% of retailers who carried the product for at least three weeks have reordered at least once (https://ibn.fm/9W75P). “Our iterative rollout of TAAT in the United States has been very strategically planned to test the initial reactions of smokers aged 21-plus when introduced to the concept of a nicotine-free and tobacco-free smoking experience, while also gauging reception of the product after it is sampled for the first time,” said Coscarella. “Over the past two months, we have had the opportunity to gather quite a bit of feedback about TAAT from smokers aged 21-plus as well as retailers and wholesalers of tobacco. I believe those insights have proven useful, as they played a role in creating our strategies for launching the TAAT online store on Wednesday, which has been a remarkable success so far. . . . “February has been a very productive month for us here at TAAT,” he continued. “In addition to launching our e-commerce portal and selling over CDN$50,000 worth of TAAT in 48 hours, we also secured our engagement with a major CPG sales agency, landed our first mainstream nationwide media coverage in ‘Forbes,’ and boosted our manufacturing rate by 233%. All of our initiatives for bringing TAAT to market in the United States are strategically coordinated, and I believe that e-commerce plays a significant role in providing us the opportunity to sell TAAT to smokers aged 21+ all across the United States while complementing our Ohio retail activities and a nationwide rollout with the CPG sales agency set to begin next week.” Under executive leadership with Big Tobacco pedigree, TAAT was launched in the United States in Q4 2020 and is focused on positioning itself in the $814 billion global tobacco industry. For more information, visit the company’s website at www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• Company reports record gross revenues of C$1,089,502 last month
• “It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” states CEO
• Record revenue comes during one of slowest e-commerce periods of year, highlighting impact the company has in the plant-based marketplace

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) saw record gross revenues last month (https://ibn.fm/qro4v). The company released its monthly numbers, noting that gross revenues for January 2021 totaled a record-breaking C$1,089,502; cost of goods sold for the month reached C$751,356.

“It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” said PlantX CEO Julia Frank. “There are many other colorful growth opportunities on the horizon, and we’re confident that our financial trajectory will reflect the remarkable and increasing value our company brings to the plant-based industry.”

PlantX Life stated that its January numbers surpassed its December 2020 gross revenues of $1,029,883, which were achieved during a highly dynamic holiday season. “This was surpassed by January 2021’s revenue, which exceeded management’s expectations given that e-commerce sales were expected to be slower following the holiday season,” the announcement noted. “This success during one of the slowest e-commerce periods of the year highlights the tremendous impact the company continues to have in the plant-based marketplace.” The announcement stated that the company’s growth reflects its commitment to meet consumer demand and continues to be driven by its innovative partnerships as well as its marketing and branding efforts.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, PlantX currently has plans to expand its product lines to include cosmetics, clothing and its own water brand.

In addition, the company uses its digital platform to build a community of like-minded consumers and to provide education. Its successful enterprise is being built and fortified through partnerships with top nutritionists, chefs and brands. For example, the company offers 20 unique pre-made meals designed by top chefs and nutritionists. These healthy meals are offered at extremely competitive prices with fast shipping and round-the-clock convenience.

The company’s commitment to customer service is the driving force behind its e-commerce platform, with innovative thinking driving its operation; the PlantX team is constantly envisioning new ways to collaborate with local restaurateurs and entrepreneurs to bring PlantX to the world. PlantX is committed to eliminating the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.

To learn more about this company, visit www.PlantX.com, www.PlantX.ca and www.Investor.PlantX.com and view the PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Calling POAI undervalued, Litchfield initiates coverage of Predictive Oncology with Buy rating, $3 price target
• The drug industry is changing as tools and technology to tailor drugs emerge, regulatory bodies focus on patients’ experiences, perspectives, needs
• Litchfield report notes several POAI strengths under “Investment Thesis” section

A growing number of companies and health providers alike are paying attention to what the FDA is calling patient-focused drug development (“PFDD”), a systematic approach to help ensure that patients’ experiences, perspectives, needs and priorities are captured and meaningfully incorporated into drug development and evaluation. In that growing market, Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been given a “Buy” rating by equity research firm Litchfield Hills Research LLC, which uses a three-tiered (buy-hold-sell) rating system (https://ibn.fm/lMp50).

“If you have ever had a medical condition that had to be treated with medication that had complex dosing requirements or complex directions for taking the medication, or side effects that made you stop, the drug industry is now paying attention,” noted Litchfield’s first analyst coverage report on Predictive Oncology. “Development of drugs to treat diseases was never tailored to any one individual because the tools to do that weren’t available, so development was generally not optimized for individual patient outcomes in terms of Active Pharmaceutical Ingredients (‘API’), side effects, getting the most out of the least amount of API (bioavailability), and medication regimen complexity and adherence.

“However, that is changing, especially as tools and technology to tailor drugs emerge, and the regulatory bodies, like the FDA, are focused on patient’s experiences, perspectives and needs,” the Litchfield report continued. “As experts in what it is like to live with their condition, patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation.”

The report notes several of POAI’s strengths under its “Investment Thesis” section, including that the company is “advancing state-of-the-art patient-centric drug development systems, which is the leading edge of current drug development, as the industry tries to reduce the time needed for commercial drug development.” Other strengths include that the company operates four subsidiaries, that its commercial business provides a stable revenue stream, and that the company has a strong balance sheet, having just completed a capital raise. In addition, the report notes that POAI has an “exceptional management team. The company has assembled an experienced management team for each of its pre-commercial subsidiaries to advance them towards commercialization.”

Calling POAI undervalued, Litchfield pronounced the following: “We are initiating coverage of Predictive Oncology Inc. with a Buy rating and a $3.00 price target. Predictive Oncology Inc. (NASDAQ: POAI) is a commercial stage biotech firm tackling cancer, assisting in vaccine development and solving medical waste issues.”

Litchfield Hills Research adheres to FINRA standards for quality and objectivity. The Litchfield Hills Research Department certifies its report is compliant with FINRA research rules 2241, 3110; that Litchfield is registered with FINRA; and that the report has been reviewed by a supervisory senior analyst. Litchfield’s price target, financial models, peer comparisons and investment thesis are developed without input from management of the company, and it performs its own due diligence.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• With Mediscan, the option of having scanning equipment at patient’s location is becoming increasingly viable
• Patent-pending Mediscan software converts ultrasound analog 2D grayscale image into digital 3D HD format
• Software can generate quality 3D medical images of broad variety of organs, including heart, lungs, tendons, skin and nerves

Since its introduction into the world of medicine, the ultrasound has become one of the most efficient, reliable ways to examine the human body in a noninvasive way. And now, this medical mainstay has become even more essential in providing quality care — proprietary technology from Healthtech Solutions (OTC: HLTT) subsidiary Mediscan Inc. can transform traditional 2D images from a portable ultrasound machine into invaluable 3D images to provide even more accurate internal views and, consequently, better diagnosis and health care. “Ultrasounds give an accurate image of body parts in the least amount of time, and even allow the patient to experience real-time results,” reported a recent Mediscan blog. “In fact, [ultrasounds] can produce a high-definition image in less than ten seconds.” That turnaround time is impressive, especially when compared to technologies such as CTs and MRIs, which can take anywhere from 24 hours to an entire week before results are available. The speed of ultrasounds becomes even more critical during emergencies, when the ability to have point-of-care ultrasound (“POCUS”) can save lives. Thanks to Mediscan, the option of having scanning equipment at a patient’s location — whether that is in an ambulance, at an assisted-living facility or even at a patient’s own home — is becoming increasingly viable. Fundamentally, the Mediscan software converts an ultrasound analog 2D grayscale image into a digital 3D HD format. This transformation can take place in traditional ultrasound locations; the Mediscan application integrates with all popular EMR systems. In addition, because the software is designed to pair with portable ultrasound machines, it can be used in less traditional settings. The exclusive software can provide valuable insight to on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (“EMS”) personnel, and technicians in isolation wards and emergency rooms. The process is simple. This patent-pending, cloud-based software application for ultrasound devices is easy to use wherever the internet is available. Once an image has been captured in 2D, it is converted using a cloud-based software application process. The now-3D image can be viewed on a computer monitor, pad or smartphone at the point of service, providing the convenience of point-of-care ultrasound with the image quality of CT or X-ray and the safety of expensive MRI technology. The software can generate quality 3D medical images of a broad variety of organs, including the heart, lungs, tendons, skin and nerves. Healthtech Solutions, through its subsidiary Mediscan Inc., offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• The COVID-19 pandemic is a year old, having devastated a number of markets since its discovery and spread were first reported in China
• While many industries have suffered worldwide during the year, the distancing requirements instituted in response to the pandemic have led buyers to turn to online retail outlets for many products
• Consumer products marketer Mohawk Group Holdings has been ideally situated to take advantage of the 44 percent growth in online commerce spending during 2020 and beyond
• Mohawk’s stock took an initial beating with the outbreak of the pandemic, but has since rebounded and rose more than 400 percent during the past three months alone
• The company’s holdings saw sales grow from $88.8 million to $144.2 million during the first nine months of 2020

Consumer products platform Mohawk Group Holdings (NASDAQ: MWK)  is riding a wave of optimism as an online retail marketer benefitting from the spike in remote access purchasing during the year-old COVID-19 pandemic. Mohawk principally leverages its proprietary technology as a third-party seller on Amazon, and grew sales revenue from $88.8 million to $144.2 million during the first nine months of 2020 reported in its most recent quarterly filing (https://ibn.fm/TyCKQ). An outside market opinion writer published this month in media outlet The Motley Fool noted that the company’s shares took a huge dive when the pandemic provoked strict commerce-limiting measures throughout the United States last year, but has also sharply rebounded. “Yes, the stock is up over 400% in the past three months, but it is still early innings for this tech-enabled CPG (consumer packaged goods) conglomerate, so don’t fool yourself into thinking you’ve missed the boat with this business,” the opinion writer, Brett Schafer, states (https://ibn.fm/yV8Jc). Schafer cited a Digital Commerce 360 report stating that e-commerce has experienced tremendous growth during the past year, with online shopping forming more than 20 percent of retail spending in the United States during 2020. The $861 billion spent online was a 44 percent increase over the previous year. Amazon captured nearly a third of the online market share, with sales growth of 54 percent during the final quarter of the year. Mohawk’s position as a third-party Amazon seller allows it to ride the commerce giant’s coattails. The company’s Artificial Intelligence Mohawk E-commerce Engine (“AIMEE”) helps it identify market opportunities then design, develop and launch products from its stable of 12 brands in categories including kitchenware and home appliances, environmental appliances, beauty products and consumer electronics. Mohawk also sells its AIMEE software to other online sellers, granting the company revenue with high margins and a huge market opportunity. The company has offices in the United States, Canada, China and the Philippines and takes advantage of its global footprint to move its products around the clock. The platform’s Fulfillment Engine helps to guide inventory location, cost optimization and use of third-party networks to cut shipping times. When Mohawk announced the acquisition of online essential oils seller Healing Solutions, LLC in early February, the company reported it expects the acquisition to help boost its net revenues for 2021 to a range between $340 million to $370 million, with net income for the year estimated to reach between $1 million and $5 million primarily in response to quarterly interest expense, net and stock-based compensation expense. Mohawk forecasts its adjusted EBITDA will be between $28 million and $32 million. For more information, visit the company’s website at www.Mohawkgp.com. NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK